Alterity Therapeutics: ATH434 Study Data Expected 1H 2024, Study Completion Nov 2024
Ticker: PRNAF · Form: 6-K · Filed: Jan 22, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: clinical-trial, biotechnology, pipeline-update, neurodegenerative-diseases
TL;DR
**Alterity's ATH434 drug trial data is coming in 1H 2024, with full study completion by November 2024, so watch for those updates!**
AI Summary
Alterity Therapeutics, a biotechnology company, issued a shareholder letter on January 22, 2024, highlighting significant progress in its drug pipeline. The company anticipates preliminary data from its ATH434-202 study in the first half of 2024, and the ATH434-201 study is expected to conclude in November 2024. This matters to investors because these milestones could provide crucial updates on the efficacy and safety of their lead drug candidate, ATH434, which targets neurodegenerative diseases, potentially impacting the stock's future valuation.
Why It Matters
Positive or negative results from the ATH434 studies could significantly impact Alterity's stock price, as the drug is a key component of their future growth and potential revenue.
Risk Assessment
Risk Level: high — As a development-stage biotechnology company, Alterity's valuation is heavily dependent on the success of its clinical trials, making it a high-risk investment.
Analyst Insight
A smart investor would closely monitor news releases from Alterity Therapeutics, particularly in 1H 2024, for the preliminary data from the ATH434-202 study, as this will be a critical catalyst for the stock.
Key Players & Entities
- Alterity Therapeutics Limited (company) — the registrant and biotechnology company
- Geoffrey P. Kempler (person) — Chairman of Alterity Therapeutics Limited
- ATH434-202 Study (other) — clinical trial for neurodegenerative diseases
- ATH434-201 Study (other) — clinical trial for neurodegenerative diseases
- January 22, 2024 (date) — date of the 6-K filing and shareholder letter
- 1H 2024 (date) — expected timeframe for preliminary data from ATH434-202 Study
- November 2024 (date) — expected completion date for ATH434-201 Study
Forward-Looking Statements
- Alterity Therapeutics' stock price will experience increased volatility around the release of preliminary ATH434-202 data. (Alterity Therapeutics) — high confidence, target: 1H 2024
- The company will issue further updates or press releases regarding the ATH434-201 study as it approaches its completion date. (Alterity Therapeutics) — medium confidence, target: Q3-Q4 2024
FAQ
What is the primary purpose of this 6-K filing by Alterity Therapeutics?
The primary purpose of this 6-K filing is to report a shareholder letter issued by Alterity Therapeutics, highlighting pipeline advances and key upcoming milestones for their drug candidates, specifically ATH434.
When is preliminary data expected from Alterity's ATH434-202 study?
Preliminary data from Alterity's ATH434-202 study is expected in the first half of 2024 (1H 2024), as stated in the Exhibit 99.1 Shareholder Letter.
When is the ATH434-201 study anticipated to be completed?
The ATH434-201 study is anticipated to be completed in November 2024, according to the Shareholder Letter (Exhibit 99.1).
Who signed the 6-K report on behalf of Alterity Therapeutics Limited?
The 6-K report was signed by Geoffrey P. Kempler, Chairman of Alterity Therapeutics Limited, on January 22, 2024.
Into which registration statements is this Form 6-K being incorporated by reference?
This Form 6-K is being incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2024-01-22 06:12:21
Filing Documents
- ea191934-6k_alterity.htm (6-K) — 13KB
- ea191934ex99-1_alterity.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-005056.txt ( ) — 39KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Shareholder Letter Reports Pipeline Advances and Milestones 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: January 22, 2024 2